Results:

Pipeline

The FDA may not approve a new treatment for multiple myeloma until at least later this year. To close this gap, the MMRF and MMRC have supported 21 treatments at various stages of development that are now in clinical trials. This support has come from research grants to support pre-clinical validation efforts (as indicated by an acorn), Biotech Investment Awards (as indicated by a “B”) to support validation and early clinical trials, and/or MMRC Phase I and II clinical trials (as indicated by a star). Continued investment in these programs represents our commitment to bringing patients the next generation of treatments as quickly as possible.